Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A brief overview of biosimilars and factors limiting their uptake.

Literature DB >> 31762845

A brief overview of biosimilars and factors limiting their uptake.

Nicholas Sosulski¹.

Abstract

Year: 2019 PMID： 31762845 PMCID： PMC6851648 DOI： 10.1177/1715163519879411

Source DB: PubMed Journal: Can Pharm J (Ott) ISSN： 1715-1635

× No keyword cloud information.

13 in total

1. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Authors: Kristin K Jørgensen; Inge C Olsen; Guro L Goll; Merete Lorentzen; Nils Bolstad; Espen A Haavardsholm; Knut E A Lundin; Cato Mørk; Jørgen Jahnsen; Tore K Kvien
Journal: Lancet Date: 2017-05-11 Impact factor: 79.321

2. Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.

Authors: Morgane Beck; Bruno Michel; Marie-Christine Rybarczyk-Vigouret; Dominique Levêque; Christelle Sordet; Jean Sibilia; Michel Velten
Journal: MAbs Date: 2016-12-08 Impact factor: 5.857

3. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.

Authors: Eline van Overbeeke; Birgit De Beleyr; Jan de Hoon; Rene Westhovens; Isabelle Huys
Journal: BioDrugs Date: 2017-10 Impact factor: 5.807

4. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.

Authors: Judy Crespi-Lofton; Jann B Skelton
Journal: J Am Pharm Assoc (2003) Date: 2017-07-06

Review 5. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.

Authors: Mourad F Rezk; Burkhard Pieper
Journal: Rheumatol Ther Date: 2017-10-14

6. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.

Authors: Emma Sullivan; James Piercy; John Waller; Christopher M Black; Sumesh Kachroo
Journal: PLoS One Date: 2017-04-14 Impact factor: 3.240

1. Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis.

Authors: Matthew L Hrin; Jeremy K Bray; Steven R Feldman
Journal: Dermatol Ther (Heidelb) Date: 2022-07-28

1 in total

A brief overview of biosimilars and factors limiting their uptake.

1. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

2. Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.

3. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.

4. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.

Review 5. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.

6. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.

7. The nocebo effect challenges the non-medical infliximab switch in practice.

8. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.

9. The nocebo effect of drugs.

10. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.

1. Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis.